TSHR and Graves disease: In a phase 1 study, this TSHR peptide mixture, termed ATX-GD-59, was then administered every 2 weeks subcutaneously to patients with treatment-naïve Graves’ hyperthyroidism, leading to normalization of hyperthyroidism in 5 of 10 patients and improvement in 7 of 10 (22).